Sign in Sign up for free

Last updated: 6 March 2024 at 7:51pm EST

Michael Pellini Net Worth




The estimated Net Worth of Michael J Pellini is at least $13.2 Million dollars as of 1 March 2021. Michael Pellini owns over 20,000 units of Adaptive Biotechnologies stock worth over $87,800 and over the last 8 years he sold ADPT stock worth over $13,016,265. In addition, he makes $88,913 as Independent Director at Adaptive Biotechnologies.

Michael Pellini ADPT stock SEC Form 4 insiders trading

Michael has made over 20 trades of the Adaptive Biotechnologies stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of ADPT stock worth $131,000 on 1 March 2021.

The largest trade he's ever made was exercising 50,000 units of Adaptive Biotechnologies stock on 14 October 2020 worth over $327,500. On average, Michael trades about 13,902 units every 63 days since 2016. As of 1 March 2021 he still owns at least 20,000 units of Adaptive Biotechnologies stock.

You can see the complete history of Michael Pellini stock trades at the bottom of the page.





Michael Pellini biography

Dr. Michael J. Pellini M.D. serves as Independent Director of the Company. Dr. Pellini currently serves as a Managing Partner of Section 32, LLC, a technology and life sciences-based venture capital fund. Dr. Pellini currently serves as a member of the board of directors of the Personalized Medicine Coalition and the Mission Hospital Foundation and several private companies. Dr. Pellini previously served as chairman of the board of directors, Chief Executive Officer and President at Foundation Medicine, Inc., a molecular information company, which was acquired by F. Hoffmann-La Roche Ltd. in 2018. Dr. Pellini holds an MD from Jefferson Medical College, an MBA from Drexel University and a BA in Economics from Boston College. Pellini is qualified to serve on our board of directors because of his medical and clinical experience in the biotechnology industry.

What is the salary of Michael Pellini?

As the Independent Director of Adaptive Biotechnologies, the total compensation of Michael Pellini at Adaptive Biotechnologies is $88,913. There are 13 executives at Adaptive Biotechnologies getting paid more, with Lance Baldo having the highest compensation of $3,707,390.



How old is Michael Pellini?

Michael Pellini is 54, he's been the Independent Director of Adaptive Biotechnologies since 2018. There are 5 older and 16 younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies Corporation is Peter Neupert, 64, who is the Lead Independent Director.

What's Michael Pellini's mailing address?

Michael's mailing address filed with the SEC is C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE, WA, 98109.

Insiders trading at Adaptive Biotechnologies

Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki..., and Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.



What does Adaptive Biotechnologies do?

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.



What does Adaptive Biotechnologies's logo look like?

Adaptive Biotechnologies Corporation logo

Complete history of Michael Pellini stock trades at Adaptive Biotechnologies

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
1 Mar 2021 ADPT Adaptive Biotechnologies Corporation Michael J Pellini
Director
 Option 20,000 $6.55 $131,000
1 Mar 2021
20,000 ↗
21 Dec 2020 ADPT Adaptive Biotechnologies Corporation Michael J Pellini
Director
 Option 25,000 $6.55 $163,750
21 Dec 2020
25,000 ↗
14 Oct 2020 ADPT Adaptive Biotechnologies Corporation Michael J Pellini
Director
 Option 50,000 $6.55 $327,500
14 Oct 2020
50,000 ↗


Adaptive Biotechnologies executives and stock owners

Adaptive Biotechnologies executives and other stock owners filed with the SEC include: